Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data.
anti-IL23
guselkumab
hidradenitis suppurativa
real life evidence
risankizumab
tildrakizumab
Journal
Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
07
2023
accepted:
10
09
2023
medline:
25
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
The treatment of hidradenitis suppurativa (HS) has always been a real challenge for dermatologists; to date, the only biologic drugs approved for HS are adalimumab, an anti-tumor necrosis factor (TNF)-α drug, authorized in 2015, and secukinumab, recently licensed. The management of this condition is challenging as the available treatments show variable results, and the course of the condition is often chronic-recurrent; therefore, it will be necessary for the future to identify new therapeutic targets for HS. In recent years, studies have focused on the development towards new therapeutic targets. The purpose of our review was to perform a comprehensive literature review of real-life data on anti-IL23 (guselkumab, tildrakizumab, and risankizumab) in HS to summarize the existing evidence on the efficacy and safety of these drugs. We selected 64 articles, among which 32 had the characteristics that we were looking for in our review. To date, the positive data expressed in real-life experiences contrast with the three existing Phase 2 studies conducted so far, where it seems that these drugs may be useful only for a subgroup of patients with HS whose features need to be elucidated. Data from Phase 3 studies and other real-life experiences, perhaps more detailed and with higher numbers, will certainly be needed to fully understand the efficacy and safety of this class of drugs.
Identifiants
pubmed: 37745273
doi: 10.2147/CCID.S418748
pii: 418748
pmc: PMC10516125
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
2525-2536Informations de copyright
© 2023 Martora et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Br J Dermatol. 2019 Nov;181(5):967-975
pubmed: 30916379
Expert Opin Biol Ther. 2022 Dec;22(12):1431-1433
pubmed: 35968665
Australas J Dermatol. 2020 Nov;61(4):e488-e490
pubmed: 32627843
J Eur Acad Dermatol Venereol. 2023 Jan;37(1):e43-e44
pubmed: 35972802
J Am Acad Dermatol. 2017 Mar;76(3):418-431
pubmed: 28057361
Clin Exp Dermatol. 2020 Jul;45(5):618-619
pubmed: 32068912
Dermatol Ther. 2021 Nov;34(6):e15116
pubmed: 34459075
J Eur Acad Dermatol Venereol. 2019 Mar;33(3):e140-e141
pubmed: 30480844
Expert Opin Drug Saf. 2023 Jan-Jun;22(5):355-362
pubmed: 37222656
Dermatol Ther. 2020 Nov;33(6):e14180
pubmed: 32790040
Int J Mol Sci. 2022 Mar 29;23(7):
pubmed: 35409118
N Engl J Med. 2016 Aug 4;375(5):422-34
pubmed: 27518661
J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e563-e565
pubmed: 35224787
J Am Acad Dermatol. 2020 Nov;83(5):e371
pubmed: 32682024
Acta Derm Venereol. 2022 Sep 28;102:adv00780
pubmed: 35971829
Lancet. 2019 Sep 7;394(10201):831-839
pubmed: 31402114
Australas J Dermatol. 2020 Aug;61(3):e373-e374
pubmed: 32285437
Clin Exp Dermatol. 2022 Jun;47(6):1186-1188
pubmed: 35179254
Ann Rheum Dis. 2022 Feb;81(2):225-231
pubmed: 34911706
Br J Dermatol. 2018 Jul;179(1):182-185
pubmed: 28654150
Clin Cosmet Investig Dermatol. 2022 Aug 16;15:1649-1658
pubmed: 35996400
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Br J Dermatol. 2021 May;184(5):966-967
pubmed: 33301601
Clin Exp Dermatol. 2023 Jul 21;48(8):938-939
pubmed: 37098176
Eur J Dermatol. 2018 Apr 1;28(2):274-275
pubmed: 29619988
Exp Dermatol. 2021 Jun;30 Suppl 1:8-17
pubmed: 34085329
Expert Opin Drug Saf. 2023 Jan;22(1):25-41
pubmed: 36718762
Dermatol Ther. 2020 May;33(3):e13456
pubmed: 32319172
Clin Exp Dermatol. 2023 Jun 5;48(6):701-703
pubmed: 36883596
J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1497-1498
pubmed: 35398945
J Am Acad Dermatol. 2022 Dec;87(6):1395-1398
pubmed: 36305697
J Cosmet Dermatol. 2022 Nov;21(11):5339-5340
pubmed: 36017741
Clin Exp Dermatol. 2022 Dec;47(12):2310-2312
pubmed: 36052835
Dermatol Ther. 2021 Sep;34(5):e15102
pubmed: 34436817
Dermatol Ther (Heidelb). 2022 Mar;12(3):701-714
pubmed: 35220545
Biomedicines. 2022 Jun 02;10(6):
pubmed: 35740325
Pharmaceuticals (Basel). 2023 Mar 31;16(4):
pubmed: 37111283
J Clin Med. 2023 Apr 30;12(9):
pubmed: 37176672
Br J Dermatol. 2023 Apr 20;188(5):588-589
pubmed: 36722365
J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e543-e545
pubmed: 35181958
Dermatol Ther. 2022 Dec;35(12):e15941
pubmed: 36239544
J Am Acad Dermatol. 2020 Jan;82(1):45-53
pubmed: 31150716
Clin Exp Dermatol. 2022 Dec;47(12):2280-2282
pubmed: 35867020
JAAD Case Rep. 2019 Jan 30;5(2):184-187
pubmed: 30740502
Exp Dermatol. 2021 Jun;30 Suppl 1:18-22
pubmed: 34085330
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e441-e442
pubmed: 33594790
J Am Acad Dermatol. 2019 Jul;81(1):76-90
pubmed: 30872156
J Dermatolog Treat. 2022 Sep;33(6):2813-2820
pubmed: 35603992
J Eur Acad Dermatol Venereol. 2021 Jan;35(1):50-61
pubmed: 32460374
J Am Acad Dermatol. 2019 Jul;81(1):265-267
pubmed: 30562567
Clin Cosmet Investig Dermatol. 2023 Jan 19;16:135-148
pubmed: 36698446
J Am Acad Dermatol. 2020 May;82(5):1045-1058
pubmed: 31604104
Clin Case Rep. 2020 Sep 10;8(12):2874-2877
pubmed: 33363841
Dermatol Ther. 2021 May;34(3):e14930
pubmed: 33665949
Expert Opin Biol Ther. 2017 May;17(5):645-657
pubmed: 28271735
Lancet. 2018 Aug 25;392(10148):650-661
pubmed: 30097359
Dermatol Ther (Heidelb). 2023 Jul;13(7):1611-1615
pubmed: 37266889
Dermatol Ther. 2022 Jan;35(1):e15197
pubmed: 34750923
Medicina (Kaunas). 2023 Apr 20;59(4):
pubmed: 37109759
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Australas J Dermatol. 2021 May;62(2):e313-e316
pubmed: 33729553
Acta Derm Venereol. 2023 Apr 19;103:adv5278
pubmed: 37073963
Dermatol Ther. 2022 Feb;35(2):e15246
pubmed: 34865295
Adv Ther. 2023 Aug;40(8):3410-3433
pubmed: 37330926
J Dermatolog Treat. 2018 Aug;29(5):441-449
pubmed: 29098911
Expert Opin Drug Saf. 2023 Jan;22(1):43-58
pubmed: 36718748
J Am Acad Dermatol. 2019 Jan;80(1):60-69.e2
pubmed: 29860040
Clin Exp Dermatol. 2022 Nov;47(11):2026-2028
pubmed: 35727206
Clin Exp Dermatol. 2022 Oct;47(10):1864-1865
pubmed: 35699658
Lancet. 2017 Jul 15;390(10091):276-288
pubmed: 28596043
J Cosmet Dermatol. 2023 Jan;22(1):28-29
pubmed: 36409574
J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e750-e751
pubmed: 35679165
Int J Dermatol. 2022 Apr;61(4):e126-e129
pubmed: 34151438
Clin Exp Dermatol. 2022 Aug;47(8):1585-1586
pubmed: 35437813
Br J Dermatol. 2019 Sep;181(3):609-611
pubmed: 30801662
Clin Cosmet Investig Dermatol. 2023 Feb 05;16:369-373
pubmed: 36776245
J Clin Med. 2023 Jan 20;12(3):
pubmed: 36769485
Biomedicines. 2022 Feb 16;10(2):
pubmed: 35203664
J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2098-2108
pubmed: 37317022
Ther Adv Chronic Dis. 2021 Nov 23;12:20406223211055920
pubmed: 34840709
Br J Dermatol. 2023 Apr 20;188(5):601-609
pubmed: 36811949
Skin Appendage Disord. 2022 May;8(3):265-268
pubmed: 35707292
Expert Rev Clin Immunol. 2019 Jan;15(1):5-12
pubmed: 30394141
Dermatol Ther (Heidelb). 2023 May;13(5):1099-1111
pubmed: 36892753
J Cosmet Dermatol. 2023 Jan;22(1):32-33
pubmed: 36156846
N Engl J Med. 2014 Jul 24;371(4):326-38
pubmed: 25007392
JAMA Dermatol. 2021 Nov 01;157(11):1279-1288
pubmed: 34406364
Lancet. 2019 Aug 17;394(10198):576-586
pubmed: 31280967
Int J Dermatol. 2022 Jul;61(7):e237-e238
pubmed: 35538737
Lancet. 2023 Mar 4;401(10378):747-761
pubmed: 36746171